A Phase II, Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2018
At a glance
- Drugs NS 065 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; Therapeutic Use
- Sponsors NS Pharma
- 12 Nov 2017 Planned End Date changed from 1 Aug 2018 to 1 Jul 2019.
- 12 Nov 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Jul 2019.
- 10 Aug 2017 Status changed from not yet recruiting to recruiting.